Search Results - "de Valeriola, D"

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on 7 days off in patients with advanced, refractory solid tumours by AWADA, A, HENDLISZ, A, PICCART, M, GIL, T, BARTHOLOMEUS, S, MANO, M, DE VALERIOLA, D, STRUMBERG, D, BRENDEL, E, HAASE, C. G, SCHWARTZ, B

“…BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor (VEGFR) inhibitor that targets tumour cell proliferation and…”
Get full text

How do cancer centres communicate clinical trials opportunities to patients on their websites? by Miqueu, P, Awada, A, De Valeriola, D, Piccart, M

Get full text

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis by Tomiak, E, Piccart, M J, Kerger, J, Lips, S, Awada, A, de Valeriola, D, Ravoet, C, Lossignol, D, Sculier, J P, Auzannet, V

“…This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose…”
Get more information

Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI) by Saghatchian, Mahasti, Hummel, Henk, Otter, Renée, de Valeriola, Dominique, Van Harten, Wim, Paradiso, Angelo, Koot, Bert, Ringborg, Ulrik, Tursz, Thomas

“…There are important gaps in the health status of citizens across Europe, as measured by life expectancy, mortality or morbidity data (Report for the European…”
Get full text

P30 The Jules Bordet Onco-Geriatric Pilot Unit: one-year report by Bernard-Marty, C, Diaz, M, Praet, J.P, Moreau, M, Cardoso, F, De Valeriola, D, Piccart, M.J

Get full text

Drugs prescribed for elderly oncologic patients hospitalized in the geriatric oncology unit of Institut Jules Bordet: Polypharmacy and impact of clinical pharmacist by Deliens, C, Vanderbeeken, M.C, Georgala, A, Filleul, O, Papadopoulou, B, Deliens, G, De Beer, A, de Valeriola, D, Piccart, M, Awada, A, Lalami, Y, Praet, J.P, Dal Lago, L

Get full text

Tobacco: deadly in any form or disguise by Boyle, Peter, Yasantha Ariyaratne, MA, Barrington, Ruth, Bartelink, Harry, Bartsch, Georg, Berns, Anton, de Valeriola, Dominique, Dinshaw, Ketayun A, Eggermont, Alexander MM, Gray, Nigel, Kakizoe, Tadao, Singh Karki, Balman, Kaslar, Miklos, Kerr, David J, Khayat, David, Khuhaprema, Thiravud, Kim, In-Hoo, Martin-Moreno, Jose, McVie, Gordon, Park, Jae-Gahb, Philip, Thierry, Ringborg, Ulrik, Rodger, Alan, Seffrin, John R, Semiglazov, Vlacimir, Soo, Khee Chee, Sun, Yun-tian, Thomas, Robert, Tursz, Thomas, Veronesi, Umberto, Wiestler, Otmar, Yoo, Keun-Young, Zatonski, Witold, Zhao, Ping

“…Since the evidence that tobacco use was harmful solidified in the 1950s, the global epidemic of tobacco-associated disease has progressively broadened and…”
Get full text

Adjuvant chemotherapy in 2005: Standards and beyond by Piccart, M.J., de Valeriola, D., Dal Lago, L., de Azambuja, E., Demonty, G., Lebrun, F., Bernard-Marty, Ch, Colozza, M., Cufer, T.

“…The 2003 St. Gallen consensus panel divided the many available adjuvant chemotherapy (CT) regimens into those with “standard efficacy” (AC×4, CMF×6) and those…”
Get full text

Improvement of European translational cancer research. Collaboration between comprehensive cancer centers by Ringborg, Ulrik, de Valeriola, Dominique, van Harten, Wim, Bosch, Antonio Llombart, Lombardo, Claudio, Nilsson, Kenneth, Philip, Thierry, Pierotti, Marco A, Riegman, Peter, Saghatchian, Mahasti, Storme, Guy, Tursz, Thomas, Verellen, Dirk

“…Even though the increasing incidence of cancer is mainly a consequence of a population with a longer life span, part of this augmentation is related to the…”
Get full text

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules by Awada, A., Giacchetti, S., Gerard, B., Eftekhary, P., Lucas, C., de Valeriola, D., Poullain, M. G., Soudon, J., Dosquet, C., Brillanceau, M.-H., Giroux, B., Marty, M., Bleiberg, H., Calvo, F., Piccart, M.

“…S 16020, a new 9-OH olivacine derivative, is a novel topoisomerase II inhibitor with activity in cell lines presenting the classical multidrug resistance…”
Get full text

Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers by Awada, A, Gil, T, Sales, F, Dubuisson, M, Vereecken, P, Klastersky, J, Moerman, C, de Valeriola, D, Piccart, M. J

“…Temozolomide (Temodal) is an oral imidazotetrazine. Increased temozolomide exposure and subsequent depletion of O-alkylguanine alkyltransferase may improve the…”
Get full text

1268 - How do cancer centres communicate clinical trials opportunities to patients on their websites? by Miqueu, P., Awada, A., De Valeriola, D., Piccart, M.

Get full text

Pioneering quality assessment in European cancer centers: a data analysis of the organization for European cancer institutes accreditation and designation program by Saghatchian, Mahasti, Thonon, Frédérique, Boomsma, Femke, Hummel, Henk, Koot, Bert, Harrison, Chris, Rajan, Abinaya, de Valeriola, Dominique, Otter, Renée, Laranja Pontes, José, Lombardo, Claudio, McGrath, Eoin, Ringborg, Ulrik, Tursz, Thomas, van Harten, Wim

“…In order to improve the quality of care in Cancer Centers (CC) and designate Comprehensive Cancer Centers (CCCs), the Organization for European Cancer…”
Get full text

Dose optimization of anthracyclines by de Valeriola, D

“…Despite the fact that anthracyclines are one of the most commonly used and active classes of anticancer agents and that their pharmacokinetic behavior has been…”
Get more information

Right atrial thrombus complicating Port-a-Cath system by Grĕgoire, J M, De Valeriola, D, Vandenbossche, J L

Get more information

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer by Hamilton, A., Biganzoli, L., Coleman, R., Mauriac, L., Hennebert, P., Awada, A., Nooij, M., Beex, L., Piccart, M., Van Hoorebeeck, I., Bruning, P., de Valeriola, D.

“…Background We performed a phase I study of polyethylene glycol (pegylated, Stealth®) liposomal doxorubicin (Caelyx®, Doxil®) using a prolonged (6-week) dose…”
Get full text

Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex by Dodion, P F, de Valeriola, D, Crespeigne, N, Kantrowitz, J D, Piccart, M, Wery, F, Kerger, J, Egorin, M J, Forrest, A, Bachur, N R

“…Forty-six patients with refractory solid malignancies received the new platinum complex [2,2-bis(aminomethyl)-1,3-propanediol-N-N']…”
Get more information

Validation of a global self-assessment and peer-review quality programme dedicated to comprehensive cancer centres: A method to assess, improve and promote quality of integrated care, research, and education in cancer centers by Saghatchian, M., Hummel, H., Otter, R., de Valeriola, D., van Harten, W., Paradiso, A., Lovey, J., Kasler, M., Fumoleau, P., Ringborg, U., Tursz, T.

“…Abstract only e17565 Background: Oncology is a specialty requiring a combination of multidisciplinary expertises, novel technology, integration of innovation…”
Get full text

Need for global action for cancer control by Boyle, P., Anderson, B.O., Andersson, L.C., Ariyaratne, Y., Auleley, G.-R., Barbacid, M., Bartelink, H., Baselga, J., Behbehani, K., Belardelli, F., Berns, A., Bishop, J., Brawley, O., Burns, H., Clanton, M., Cox, B., Currow, D., Dangou, J.-M., de Valeriola, D., Dinshaw, K., Eggermont, A., Fitzpatrick, J., Forstmane, M., Garaci, E., Gavin, A.T., Kakizoe, T., Kasler, M., Keita, N., Kerr, D., Khayat, D., Khleif, S., Khuhaprema, T., Knezevic, T., Kubinova, R., Mallath, M., Martin-Moreno, J., McCance, D., McVie, J.G., Merriman, A., Ngoma, T., Nowacki, M., Orgelbrand, J., Park, J.-G., Pierotti, M., Ashton, L.P., Puska, P., Escobar, C.V.R., Rajan, B., Rajkumar, T., Ringborg, U., Robertson, C., Rodger, A., Roovali, L., Santini, L.A., Sarhan, M., Seffrin, J., Semiglazov, V., Shrestha, B.M., Soo, K.C., Stamenic, V., Tamblyn, C., Thomas, R., Tuncer, M., Tursz, T., Vaitkiene, R., Vallejos, C., Veronesi, U., Wojtyla, A., Yach, D., Yoo, K.-Y., Zatonski, W., Zaridze, D., Zeng, Y.-X., Zhao, P., Zheng, T.

Get full text

Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs by DE VALERIOLA, D. L, ROSS, D. D, FORREST, A, CUDDY, D. P, EGORIN, M. J

“…We have developed a pharmacokinetic/pharmacodynamic approach that integrates the disposition, cytotoxic activity and interaction of anticancer drugs…”
Get full text